Drug Price Trends for NDC 59310-0410

Average Pharmacy Cost for 59310-0410

Drug Name	NDC	Price/Unit ($)	Unit	Date
QNASL 80 MCG NASAL SPRAY	59310-0410-12	30.31449	GM	2026-01-01
QNASL 80 MCG NASAL SPRAY	59310-0410-12	28.87094	GM	2025-12-17
QNASL 80 MCG NASAL SPRAY	59310-0410-12	28.86846	GM	2025-11-19
QNASL 80 MCG NASAL SPRAY	59310-0410-12	28.87259	GM	2025-10-22
QNASL 80 MCG NASAL SPRAY	59310-0410-12	28.88780	GM	2025-09-17
QNASL 80 MCG NASAL SPRAY	59310-0410-12	28.88670	GM	2025-08-20
QNASL 80 MCG NASAL SPRAY	59310-0410-12	28.89737	GM	2025-07-23

Best Wholesale Price for NDC 59310-0410

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 59310-0410

Last updated: March 7, 2026

What is NDC 59310-0410?

NDC 59310-0410 is identified as Aflibercept Injection, a biopharmaceutical agent used primarily for indications including wet age-related macular degeneration (AMD), diabetic macular edema (DME), and proliferative diabetic retinopathy (PDR). It is marketed under the brand name Eylea, developed by Regeneron Pharmaceuticals.

---

Market Size and Demand Drivers

Current Market Size

• The global ophthalmic drugs market was valued at approximately USD 13 billion in 2022.
• The anti-VEGF segment, including Aflibercept, accounted for roughly 45% of this market, estimated at USD 5.85 billion.
• The U.S. segment dominates, representing approximately 65% of global demand.

Key Demand Factors

• Increasing prevalence of AMD, DME, and PDR.
• Aging populations worldwide.
• Growing awareness and early detection of ocular diseases.
• The proven efficacy of intravitreal anti-VEGF treatments.

Market Penetration

• Aflibercept holds around 35% of the anti-VEGF market share in retina-related indications.
• Multinational competitors include Lucentis (Ranibizumab) and Beovu (Brolucizumab).

---

Regulatory Status and Approvals

Region	Approval Status	Notes
U.S.	FDA approval in 2011	Widely used for AMD, DME, PDR
EU	EMA approval in 2012	Same indications, broader market
Japan	PMDA approval in 2012	Key Asian market

Patent and Exclusivity

• U.S. patent protection extends until 2032.
• Patent thickets impact biosimilars' market entry.

---

Pricing Overview

Current Price per Dose

Product	Average Price (USD)	Dosage/Packaging	Notes
Eylea	$2,100 - $2,300	40 mg/0.1 mL (vial)	Local variations, insurance adjustments
Lucentis	~$2,000	0.3 mg/0.23 mL	Alternative anti-VEGF therapy
Brolucizumab	~$1,900	6 mg/0.05 mL	Newer entry, lower dose per administration

Reimbursement Landscape

• U.S.: Reimbursed through Medicare, private insurers.
• EU: Managed via national health systems.
• Pricing pressures due to biosimilar development.

---

Future Price Projections (2023-2028)

Year	Estimated Price per Dose (USD)	Assumptions
2023	$2,200	Current list prices, no major policy shifts
2024	$2,050	Slight discounts, increased biosimilar competition
2025	$2,000	Market saturation, price negotiation effects
2026	$1,950	Biosimilar entries, market share erosion
2027	$1,900	Biosimilar availability, pricing adjustments
2028	$1,850	Market stabilization, patent expiries in view

Drivers of Price Changes

• Biosimilar competition emerging from biosimilar developers, including Coherus, Samsung Bioepis, and others.
• Increasing biosimilar approvals in major markets.
• Negotiated pricing in healthcare systems.
• Patent expiries and legal challenges.

---

Competitive Landscape

Competitor	Product Name	Indication	Market Share (2022)	Price Range (USD)	Approval Year
Regeneron	Eylea	AMD, DME, PDR	35%	$2,100-$2,300	2011
Novartis/Genentech	Lucentis	AMD, DME	25%	~$2,000	2006
Bayer/Biotech	Brolucizumab	AMD	10%	~$1,900	2019

Key Market Risks

• Patent expirations threaten exclusivity from 2022-2032.
• Biosimilar market entry exerts downward price pressure.
• Regulatory shifts affecting reimbursement.
• Medical guidelines favoring alternative therapies.

---

Key Takeaways

• NDC 59310-0410 (Aflibercept) remains a key player in retinal disease treatment with stable demand driven by demographic trends.
• The market is approaching increased biosimilar competition, forecasted to reduce prices by approximately 15-20% over the next five years.
• U.S. and EU markets are dominant but face divergent regulatory pathways for biosimilar entry.
• Pricing innovations, such as pre-filled syringes and combination therapies, could influence future price points.
• Patent protections extend into the early 2030s, providing some pricing stability but with increasing pressures from biosimilar entrants.

---

FAQs

1. What factors influence Aflibercept pricing?
   Reimbursement policies, biosimilar competition, patent status, and negotiation power of payers.

2. Are biosimilars expected to replace Aflibercept?
   Biosimilars are projected to capture a significant share, especially post-patent expiry, bringing prices down.

3. How does Aflibercept compare to other anti-VEGF treatments?
   It has comparable efficacy but slightly different dosing schedules, influencing patient adherence and overall cost.

4. What regulatory changes could impact future prices?
   Approval of biosimilars, changes in patent law, and reimbursement shifts.

5. When will biosimilar competition significantly impact pricing?
   Likely starting around 2025-2026, with increased market penetration by biosimilars.

---

References

1. MarketsandMarkets. (2023). Ophthalmic Drugs Market. [Report]
2. U.S. Food and Drug Administration. (2011). Eylea (Aflibercept) approval details.
3. European Medicines Agency. (2012). Summary of product characteristics for Eylea.
4. IQVIA. (2022). Global Ophthalmology Market Data.
5. FDA. (2021). Biosimilar Development and Regulations.

---